InternationalUSRemember you can easily switch between MIP US and MIP International at any time

Kyle Bass’s success rate at the PTAB – an update



Michael Loney


Hedge fund manager Kyle Bass has not gotten any holiday cheer from the Patent Trial and Appeal Board, with two of his petitions challenging pharmaceutical patents denied this month. The Board has now ruled on 16 of his inter partes review petitions

December has not been kind to hedge fund manager Kyle Bass’s efforts to invalidate pharmaceutical patents through Patent Trial and Appeal Board proceedings. 

The Board this month has denied institution of two of his inter partes review petitions. Its decisions on December 8 and 17 both involved patents covering Pozen’s Vimovo arthritis pain treatment, which is marketed in the US by Horizon Pharma.

For those keeping score, the PTAB has now given an institution decision in 16 of the 33 petitions filed by the Coalition for Affordable Drugs, the coalition set up by Bass and Erich Spangenberg to attack pharma patents.

This means the board has now given an institution decision on almost half of the Coalition for Affordable Drugs petitions (see table below). 

Kyle BassBass’s success rate for institution now stands at 44%, with the PTAB instituting trial for seven IPRs and denying nine. This is down from the heady days of October, when Bass could boast a 54% rate of success after the Board had instituted seven of the 13 petitions it had decided up until then. 

The Board has denied three petitions in a row since then.

Bass will be hoping to break this losing streak next month when the Board is likely to give more decisions, including on two more IPRs challenging the Vimovo treatment. 

The PTAB has given decisions on all of Bass’s petitions filed until the end of June. Next up it must decide on the 12 petitions the Coalition filed in August and the five petitions filed in September.

Interestingly, Bass and Spangenberg in November also filed two petitions with just their two names listed, and no Coalition for Affordable Drugs. These petitions challenged patents owned by Alpex Pharma and Fresenius. 

The Coalition for Affordable Drugs' IPR petitions*
IPR number Date filed Law firm used by the Coalition Patent number Patent owner Drug used in Instituted?
IPR2015-00720 February 10 Skiermont Puckett 8,663,685 Acorda Therapeutics Ampyra NO
IPR2015-00817 February 27 Skiermont Puckett 8,007,826 Acorda Therapeutics Ampyra NO
IPR2015-00988 April 1 Skiermont Puckett 6,773,720 Cosmo Technologies/Nogra Pharma/Shire Development/Shire Inc/Shire Pharmaceuticsl Development Lialda YES
IPR2015-00990 April 1 Merchant & Gould 7,056,886 NPS Pharmaceuticals/Shire North American Group Gattex YES
IPR2015-01018 April 6 Merchant & Gould 7,895,059 Jazz Pharmaceuticals Xyrem NO
IPR2015-01076 April 20 Merchant & Gould 8,754,090 Pharmacyclics Imbruvica NO
IPR2015-01086 April 22 Neifeld IP Law 8,759,393 Biogen International Tecfidera NO
IPR2015-01102 April 23 Skiermont Puckett 6,315,720 Celgene Corporation Revlimid YES
IPR2015-01096 April 23 Skiermont Puckett 6,315,720 Celgene Corporation Revlimid YES
IPR2015-01103 April 23 Skiermont Puckett 6,315,720 Celgene Corporation Revlimid YES
IPR2015-01092 April 23 Skiermont Puckett 6,045,501 Celgene Corporation Pomalyst, Revlimid and Thalomid YES
IPR2015-01093 April 23 Merchant & Gould 7,056,886 NPS Pharmaceuticals/Shire North American Group Gattex YES (for some claims)
IPR2015-01136 May 1 Neifeld IP Law 8,399,514 Biogen MA Tecfidera NO
IPR2015-01169 May 7 Merchant & Gould 5,635,517 Celgene Corporation Pomalys NO
IPR2015-01241 May 21 Conley Rose 6,926,907 Pozen (Horizon Pharma bought the rights to the drug in November 2013)) Vimovo NO
IPR2015-01344 June 5 Conley Rose 8,858,996 Horizon Pharma/Pozen Vimovo NO
IPR2015-01680 August 7 Conley Rose 8,852,636 Pozen (Horizon Pharma bought the rights to the drug in November 2013)) Vimovo
IPR2015-01718 August 12 Conley Rose 8,945,621 Horizon Pharma/Pozen Vimovo
IPR2015-01723 August 13 Cunningham Swaim/Winstead 6,967,208 Bristol Myers Squibb Pharma Eliquis
IPR2015-01776 August 20 Merchant & Gould  7,582,621 Anacor/Sandoz Kerydin
IPR2015-01785 August 20 Merchant & Gould 7,767,657 Anacor/Sandoz Kerydin
IPR2015-01780 August 20 Merchant & Gould 7,767,657 Anacor/Sandoz Kerydin
IPR2015-01792 August 22 Neifeld IP Law 8,163,522 Amgen/Hoffmann-La Roche/Immunex Enbrel
IPR2015-01799 August 24 Law Offices of Gregory J Gonsalves/McNeeley Hare & War 8,835,460 Insys Pharma Subsys
IPR2015-01797 August 24 Law Offices of Gregory J Gonsalves/McNeeley Hare & War 8,835,459 Insys Pharma Subsys
IPR2015-01800 August 24 Law Offices of Gregory J Gonsalves/McNeeley Hare & War 8,486,972 Insys Pharma Subsys
IPR2015-01835 August 28 Law Offices of Gregory J Gonsalves/McNeeley Hare & War 8,618,135 Aegerion Pharmaceuticals/Trustees of The University of Pennsylvania Juxtapid
IPR2015-01836 August 28 Law Offices of Gregory J Gonsalves/McNeeley Hare & War 7,932,268 Aegerion Pharmaceuticals/Trustees of The University of Pennsylvania Juxtapid
IPR2015-01850 September 2 Skiermont Puckett 8,440,703 Acorda Therapeutics Ampyra
IPR2015-01853 September 2 Skiermont Puckett 8,007,826 Acorda Therapeutics Ampyra
IPR2015-01858 September 3 Skiermont Puckett 8,354,437 Acorda Therapeutics Ampyra
IPR2015-01857 September 3 Skiermont Puckett 8,663,685 Acorda Therapeutics Ampyra
IPR2015-01993 September 28 Neifeld IP Law 8,399,514 Biogen MA Tecfidera
All of the IPRs list the petitioners as the Coalition for Affordable Drugs, J Kyle Bass, Erich Spangenberg, Hayman Capital Management, various Hayman funds, IP Navigation Group, and nXn Partners
Source: Docket Navigator

IPR petitions filed listing only Kyle Bass and Erich Spangenberg
IPR number Date filed Law firm used Patent number Patent owner Drug used in
IPR2016-00245 November 24 Law Offices of Gregory J Gonsalves/McNeeley Hare & War 8,440,170 Alpex Pharma Suprenza
IPR2016-00254 November 25 Law Offices of Gregory J Gonsalves/McNeeley Hare & War 8,476,010 Fresenius Kabi Diprivan
Source: Docket Navigator


Comments






profile

Managing IP

ManagingIP

ManagingIP profile

RT @CIGIonline: What renegotiating #NAFTA #IP rules could mean for Canada’s winemakers, sculptors, authors & musicians: https://t.co/7xuoxk

Jul 26 2017 03:21 ·  reply ·  retweet ·  favourite
ManagingIP profile

RT @T_Hackett: #MarrakeshTreaty soon enters into force in two @EIFLnet partner countries: #Kyrgyzstan on 15 August and #Kenya on 2 Sept. Lo…

Jul 26 2017 02:45 ·  reply ·  retweet ·  favourite
ManagingIP profile

RT @StevePeers: ECJ, external trade AG opinion: treaty on geographical indications within common trade policy (exclusive power): https://t…

Jul 26 2017 02:45 ·  reply ·  retweet ·  favourite

Popular Posts

Blog Archive

IP-related blogs

1709 Copyright Blog

Afro-IP

AIA blog

Art and Artifice

China IPR

Class 99

Domain Incite

FOSS Patents

Green Patent Blog

Incontestable

IP CloseUp

IP Dragon

IP finance

IP Kat

IP Komodo

IP tango

IP Watchdog

IPEG

MARQUES Class 46

Orange Book Blog

Patent Baristas

PatentlyO

PatLit

SPC Blog

Spicy IP

The Trademark Blog

The TTABlog